Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
135.42
+0.46 (0.34%)
Dec 20, 2024, 4:00 PM EST - Market closed
Neurocrine Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 385.9 | 249.7 | 154.5 | 89.6 | 407.3 | 37 | Upgrade
|
| Depreciation & Amortization | 25.7 | 21.3 | 15.6 | 10.9 | 8.6 | 7.4 | Upgrade
|
| Other Amortization | 0.7 | 0.7 | 1.2 | 17.3 | 21.4 | 20.3 | Upgrade
|
| Loss (Gain) From Sale of Investments | -20.7 | -46.7 | -27.1 | -13.5 | 17.7 | 13 | Upgrade
|
| Stock-Based Compensation | 167.2 | 194.3 | 173.1 | 134.2 | 100 | 75.3 | Upgrade
|
| Other Operating Activities | 70.8 | -57.6 | 89.5 | 1.3 | -288.6 | -1.2 | Upgrade
|
| Change in Accounts Receivable | -63.2 | -89.3 | -162.2 | -28.4 | -30.5 | -69.2 | Upgrade
|
| Change in Inventory | -8.4 | 5.4 | -2.6 | -2.5 | -10.7 | -6.4 | Upgrade
|
| Change in Accounts Payable | -121.7 | 64.3 | 114.6 | 56.8 | 26.9 | 54 | Upgrade
|
| Change in Other Net Operating Assets | 26.1 | 47.8 | -17.2 | -9.2 | -23.6 | 16.8 | Upgrade
|
| Operating Cash Flow | 476.4 | 389.9 | 339.4 | 256.5 | 228.5 | 147 | Upgrade
|
| Operating Cash Flow Growth | 16.37% | 14.88% | 32.32% | 12.25% | 55.44% | 44.97% | Upgrade
|
| Capital Expenditures | -36.3 | -28.3 | -16.5 | -23.4 | -10.9 | -14.7 | Upgrade
|
| Cash Acquisitions | - | - | -42.7 | - | - | - | Upgrade
|
| Investment in Securities | -224 | -438.8 | -117.9 | -106.8 | 15 | -127.5 | Upgrade
|
| Other Investing Activities | - | - | - | - | - | -68.9 | Upgrade
|
| Investing Cash Flow | -260.3 | -467.1 | -177.1 | -130.2 | 4.1 | -211.1 | Upgrade
|
| Long-Term Debt Repaid | - | - | -279 | -0.1 | -186.9 | - | Upgrade
|
| Net Debt Issued (Repaid) | -308.8 | - | -279 | -0.1 | -186.9 | - | Upgrade
|
| Issuance of Common Stock | 147.5 | 65.3 | 44.7 | 27.5 | 29.1 | 32.4 | Upgrade
|
| Financing Cash Flow | -161.3 | 65.3 | -234.3 | 27.4 | -157.8 | 32.4 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.6 | 0.3 | -1.3 | - | - | - | Upgrade
|
| Net Cash Flow | 55.4 | -11.6 | -73.3 | 153.7 | 74.8 | -31.7 | Upgrade
|
| Free Cash Flow | 440.1 | 361.6 | 322.9 | 233.1 | 217.6 | 132.3 | Upgrade
|
| Free Cash Flow Growth | 14.40% | 11.99% | 38.52% | 7.12% | 64.47% | 72.72% | Upgrade
|
| Free Cash Flow Margin | 19.62% | 19.16% | 21.69% | 20.56% | 20.81% | 16.79% | Upgrade
|
| Free Cash Flow Per Share | 4.25 | 3.58 | 3.26 | 2.38 | 2.22 | 1.38 | Upgrade
|
| Cash Interest Paid | 3.5 | 3.8 | 6.6 | 8.6 | 11.6 | 11.6 | Upgrade
|
| Cash Income Tax Paid | 191 | 51.5 | 14.4 | 5.1 | 15.3 | 0.5 | Upgrade
|
| Levered Free Cash Flow | 328.06 | 405.08 | 244.39 | 265.75 | 278.59 | 204.56 | Upgrade
|
| Unlevered Free Cash Flow | 330.24 | 407.25 | 247.63 | 264.58 | 277.69 | 204.26 | Upgrade
|
| Change in Net Working Capital | 202.8 | 26.8 | 80.2 | -13 | 24.7 | 5.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.